Effects of LOTRIGA in chronic heart failure patients with hyperlipidemia:a prospective randomized,open-label,parallel group comparison study

Effects of LOTRIGA in chronic heart failure patients with hyperlipidemia:a prospective randomized,open-label,parallel group comparison study - Effects of LOTRIGA in chronic heart failure patients with hyperlipidemia(EPA/DHA study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011468

Enrollment

Registered

2013-08-15

Start date

2013-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure with hyperlipidemia

Interventions

LOTRIGA group non-LOTRIGA group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.LVEF<50% even though standard medical treatments for heart failure 2.stable out patient for more than 3 months 3.patients who are not enrolled in other clinical trial 4.written consent

Exclusion criteria

Exclusion criteria: 1.patients who are planned PCI or CABG 2.patients who have myocardial ischemia 3.unstable patient due to non-cardiac disease 4.pregnant woman 5.patients who are judged to be inappropriate to this study

Design outcomes

Primary

Measure	Time frame
a rate of change of LVEF after dosage from baseline to 12-months follow-up	—

Secondary

Measure	Time frame
a rate of change of LVEF after dosage from baseline to 6-months follow-up major adverse cardiac event(cardiovascular death,non-fatal MI,UAP,hospitalization for heart failure,stroke,other cardiovascular events)	—

Countries

Japan

Contacts

Public ContactYusuke Nakano

Aichi Medical University Department of Cardiology

nakanoy@aichi-med-u.ac.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026